feedback

Course Director

Lecia V. Sequist, MD, MPH
Lecia V. Sequist, MD, MPH

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Faculty

Mary Jo Fidler
Mary Jo Fidler, MD

Rush University Medical Center
Chicago, Illinois

Jyoti D. Patel
Jyoti D. Patel, MD

The University of Chicago
Chicago, Illinois

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CE
Credit Amount:1.5 Credits
Release Date:2017-Oct-27
Expiration Date:2018-Oct-26
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

The management of advanced/metastatic EGFR-positive NSCLC is in a state of flux, and the treatment landscape is being shaken up by new, exciting research and clinical trial findings. In this educational activity, which is based on a Live Master Class and Practicum, experts in lung cancer explore the latest evidence and provide guidance for how to effectively navigate the molecular testing options throughout the continuum of the disease, as well as the complex clinical decisions regarding choice of EGFR TKI therapy in the first-line setting and beyond.

Upon completion of this activity, participants will be able to:

  • Discuss the role and optimal use of tissue- and blood-based biomarker testing methodologies for detection of EGFR mutations in different settings throughout the disease course
  • Analyze the efficacy/safety and clinical roles of standard and novel EGFR TKIs and combination strategies in the first-line treatment of advanced EGFR mutation-positive NSCLC
  • Assess the efficacy/safety and clinical roles of approved and investigational therapies and combinations for management of NSCLC with acquired resistance to initial EGFR TKIs
  • Implement best practices for individualized, genotype-directed, evidence-based management of patients with NSCLC exhibiting EGFR mutations throughout the continuum of advanced disease

Target Audience

This activity has been designed to meet the educational needs of thoracic oncology specialists and other healthcare professionals involved in the management of patients with lung cancer.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of advanced EGFR mutation-positive NSCLC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 27, 2017 - October 26, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 12 months.

Course Director and Moderator

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Lecia V. Sequist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Genentech, Inc.; Merrimack Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Lecia V. Sequist, MD, MPH, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

Faculty

Mary Jo Fidler, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Cell Therapy
Rush University Medical Center
Chicago, Illinois

Mary Jo Fidler, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Celgene Corporation; Genentech, Inc.; and Merck & Co., Inc.
Advisory Board for AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support from Spouse who is also a consultant for Genentech, Inc.
Mary Jo Fidler, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

Jyoti D. Patel, MD
Professor of Medicine
Section of Hematology\Oncology
The University of Chicago
Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc. and ARIAD Pharmaceuticals, Inc.
Jyoti D. Patel, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Targeted therapies and/or combination for EGFR-positive lung cancer and platforms for detecting EGFR mutations.

CME Reviewer

Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York

Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Pamela Ash, RN, MSN, CBCN
Supportive Care Nurse Clinician
Mary Babb Randolph Cancer Center Clinic
West Virginia University
Morgantown, West Virginia

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Providership

This CME/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.